Downregulation of CD147 expression by RNA interference inhibits HT29 cell proliferation, invasion and tumorigenicity in vitro and in vivo

International Journal of Oncology

Volumn 43, Issue 6, 2013, Pages 1885-1894

  Li, Rui ^a,b   Pan, Yuqin ^b   He, Bangshun ^b   Xu, Yeqiong ^b   Gao, Tianyi ^b   Song, Guoqi ^b   Sun, Huiling ^a,b   Deng, Qiwen ^b   Wang, Shukui ^b  

^a NANJING NORMAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

CD147; Colorectal cancer; HT29 cells; RNA interference

Indexed keywords

CD147 ANTIGEN; CISPLATIN; GELATIN; GELATINASE A; GELATINASE B; LACTIC ACID; MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 4; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CELL INVASION; CELL PROLIFERATION; CHEMOSENSITIVITY; COLORECTAL CANCER; CONTROLLED STUDY; EXPRESSION VECTOR; FEMALE; GENE SILENCING; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR GROWTH; WESTERN BLOTTING; WST-8 ASSAY; ZYMOGRAPHY;

ANTIGENS, CD147; ANTINEOPLASTIC AGENTS; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; LACTIC ACID; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MONOCARBOXYLIC ACID TRANSPORTERS; MUSCLE PROTEINS; NEOPLASM INVASIVENESS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SYMPORTERS;

EID: 84891918388     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2108     Document Type: Article

References (36)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Center MM, Jemal A, Smith RA and Ward E: Worldwide variations in colorectal cancer. CA Cancer J Clin 59: 366-378, 2009.
3. Stein U and Schlag PM: Clinical, biological, and molecular aspects of metastasis in colorectal cancer. Recent Results Cancer Res 176: 61-80, 2007.
4. Polette M, Gilles C, Marchand V, et al: Tumor collagenase stimulatory factor (TCSF) expression and localization in human lung and breast cancers. J Histochem Cytochem 45: 703-709, 1997.
5. Jiang JL, Zhou Q, Yu MK, Ho LS, Chen ZN and Chan HC: The involvement of HAb18G/CD147 in regulation of store-operated calcium entry and metastasis of human hepatoma cells. J Biol Chem 276: 46870-46877, 2001.
6. Riethdorf S, Reimers N, Assmann V, et al: High incidence of EMMPRIN expression in human tumors. Int J Cancer 119: 1800-1810, 2006.
7. Muramatsu T and Miyauchi T: Basigin (CD147): a multifunctional transmembrane protein involved in reproduction, neural function, inflammation and tumor invasion. Histol Histopathol 18: 981-987, 2003.
8. Rosenthal EL, Shreenivas S, Peters GE, Grizzle WE, Desmond R and Gladson CL: Expression of extracellular matrix metalloprotease inducer in laryngeal squamous cell carcinoma. Laryngoscope 113: 1406-1410, 2003.
9. Hanata K, Yamaguchi N, Yoshikawa K, et al: Soluble EMMPRIN (extra-cellular matrix metalloproteinase inducer) stimulates the migration of HEp-2 human laryngeal carcinoma cells, accompanied by increased MMP-2 production in fibroblasts. Arch Histol Cytol 70: 267-277, 2007.
10. Sameshima T, Nabeshima K, Toole BP, et al: Expression of emmprin (CD147), a cell surface inducer of matrix metalloproteinases, in normal human brain and gliomas. Int J Cancer 88: 21-27, 2000.
11. Stenzinger A, Wittschieber D, von Winterfeld M, et al: High extracellular matrix metalloproteinase inducer/CD147 expression is strongly and independently associated with poor prognosis in colorectal cancer. Hum Pathol 43: 1471-1481, 2012.
12. Zhu S, Chu D, Zhang Y, et al: EMMPRIN/CD147 expression is associated with disease-free survival of patients with colorectal cancer. Med Oncol 30: 369, 2013.
13. Pan Y, He B, Song G, et al: CD147 silencing via RNA interference reduces tumor cell invasion, metastasis and increases chemosensitivity in pancreatic cancer cells. Oncol Rep 27: 2003-2009, 2012.
14. Lynch CC and Matrisian LM: Matrix metalloproteinases in tumor-host cell communication. Differentiation 70: 561-573, 2002.
15. Caudroy S, Polette M, Tournier JM, et al: Expression of the extracellular matrix metalloproteinase inducer (EMMPRIN) and the matrix metalloproteinase-2 in bronchopulmonary and breast lesions. J Histochem Cytochem 47: 1575-1580, 1999.
16. Caudroy S, Polette M, Nawrocki-Raby B, et al: EMMPRIN-mediated MMP regulation in tumor and endothelial cells. Clin Exp Metastasis 19: 697-702, 2002.
17. Biswas C, Zhang Y, DeCastro R, et al: The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 55: 434-439, 1995.
18. Menashi S, Serova M, Ma L, Vignot S, Mourah S and Calvo F: Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells. Cancer Res 63: 7575-7580, 2003.
19. Guo H, Li R, Zucker S and Toole BP: EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Cancer Res 60: 888-891, 2000.
20. Philp NJ, Ochrietor JD, Rudoy C, Muramatsu T and Linser PJ: Loss of MCT1, MCT3, and MCT4 expression in the retinal pigment epithelium and neural retina of the 5A11/basigin-null mouse. Invest Ophthalmol Vis Sci 44: 1305-1311, 2003.
21. Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN and Halestrap AP: CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J 19: 3896-3904, 2000.
22. Yang JM, Xu Z, Wu H, Zhu H, Wu X and Hait WN: Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res 1: 420-427, 2003.
23. Misra S, Ghatak S, Zoltan-Jones A and Toole BP: Regulation of multidrug resistance in cancer cells by hyaluronan. J Biol Chem 278: 25285-25288, 2003.
24. Yan L, Zucker S and Toole BP: Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost 93: 199-204, 2005.
25. Kanekura T, Chen X and Kanzaki T: Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer 99: 520-528, 2002.
26. Zhu C, Pan Y, He B, et al: Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to cisplatin in laryngeal carcinoma Hep2 cells. Oncol Rep 25: 425-432, 2011.
27. Lochter A and Bissell MJ: An odyssey from breast to bone: multi-step control of mammary metastases and osteolysis by matrix metalloproteinases. APMIS 107: 128-136, 1999.
28. Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141: 52-67, 2010.
29. Roy R, Yang J and Moses MA: Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 27: 5287-5297, 2009.
30. Herszenyi L, Hritz I, Lakatos G, Varga MZ and Tulassay Z: The behavior of matrix metalloproteinases and their inhibitors in colorectal cancer. Int J Mol Sci 13: 13240-13263, 2012.
31. Gallagher SM, Castorino JJ, Wang D and Philp NJ: Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res 67: 4182-4189, 2007.
32. + symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc Natl Acad Sci USA 108: 16663-16668, 2011.
33. Zou W, Yang H, Hou X, Zhang W, Chen B and Xin X: Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to paclitaxel in HO-8910pm cells. Cancer Lett 248: 211-218, 2007.
34. Jia L, Wang H, Qu S, Miao X and Zhang J: CD147 regulates vascular endothelial growth factor-A expression, tumorigenicity, and chemosensitivity to curcumin in hepatocellular carcinoma. IUBMB Life 60: 57-63, 2008.
35. Raymond E, Faivre S, Chaney S, Woynarowski J and Cvitkovic E: Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1: 227-235, 2002.
36. Virag P, Perde-Schrepler M, Fischer-Fodor E, et al: Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines. Anticancer Drugs 23: 1032-1038, 2012.